These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 31151303)

  • 1. Hyperprogression under Immunotherapy.
    Frelaut M; Le Tourneau C; Borcoman E
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy.
    Frelaut M; du Rusquec P; de Moura A; Le Tourneau C; Borcoman E
    BioDrugs; 2020 Aug; 34(4):463-476. PubMed ID: 32394415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudoprogression and hyperprogression after checkpoint blockade.
    Wang Q; Gao J; Wu X
    Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.
    Failing JJ; Dudek OA; Marin Acevedo JA; Chirila RM; Dong H; Markovic SN; Dronca RS
    Future Oncol; 2019 Aug; 15(22):2645-2656. PubMed ID: 31298573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperprogression as a distinct outcome after immunotherapy.
    Fuentes-Antrás J; Provencio M; Díaz-Rubio E
    Cancer Treat Rev; 2018 Nov; 70():16-21. PubMed ID: 30053725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Response and Progression to Immunotherapy.
    Borcoman E; Nandikolla A; Long G; Goel S; Le Tourneau C
    Am Soc Clin Oncol Educ Book; 2018 May; 38():169-178. PubMed ID: 30231380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
    Zhou L; Zhang M; Li R; Xue J; Lu Y
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3269-3279. PubMed ID: 32857178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel patterns of response under immunotherapy.
    Borcoman E; Kanjanapan Y; Champiat S; Kato S; Servois V; Kurzrock R; Goel S; Bedard P; Le Tourneau C
    Ann Oncol; 2019 Mar; 30(3):385-396. PubMed ID: 30657859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
    Denis M; Duruisseaux M; Brevet M; Dumontet C
    Front Immunol; 2020; 11():492. PubMed ID: 32265935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Djunadi TA; Oh Y; Lee J; Yu J; Chung LI; Lee Y; Kim L; Hong T; Lee S; Shah Z; Park JH; Yoon SM; Chae YK
    Clin Lung Cancer; 2024 Jun; 25(4):365-375.e14. PubMed ID: 38644088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprogression after immunotherapy: A comprehensive review.
    Okan Cakir M; Kirca O; Gunduz S; Ozdogan M
    J BUON; 2019; 24(6):2232-2241. PubMed ID: 31983088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
    Mushti SL; Mulkey F; Tang S; Singh H; Lemery SJ; Goldberg KB; Sridhara R; Keegan P; Kluetz PG; Pazdur R; Theoret MR; Beaver JA
    Curr Oncol Rep; 2020 Aug; 22(11):116. PubMed ID: 32851542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperprogressive disease in patients receiving immune checkpoint inhibitors.
    Zhang H; Fang X; Li D; Yang M; Yu L; Ding Y; Shen H; Yuan Y
    Curr Probl Cancer; 2021 Jun; 45(3):100688. PubMed ID: 33334611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma.
    Schuiveling M; Tonk EHJ; Verheijden RJ; Suijkerbuijk KPM
    Cancer Immunol Immunother; 2021 May; 70(5):1491-1496. PubMed ID: 32929554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy.
    Mandal S; Ray B; Baniya Sharma S; Poulose J; Kasireddy V
    Cureus; 2021 Sep; 13(9):e17992. PubMed ID: 34667669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy.
    Solinas C; Porcu M; Hlavata Z; De Silva P; Puzzoni M; Willard-Gallo K; Scartozzi M; Saba L
    Crit Rev Oncol Hematol; 2017 Dec; 120():13-21. PubMed ID: 29198327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
    Aide N; Hicks RJ; Le Tourneau C; Lheureux S; Fanti S; Lopci E
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):238-250. PubMed ID: 30291373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprogression: A novel response pattern under immunotherapy.
    Han XJ; Alu A; Xiao YN; Wei YQ; Wei XW
    Clin Transl Med; 2020 Sep; 10(5):e167. PubMed ID: 32997401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics.
    Singla R; Gupta A; Batra U; Chaturvedi A; Rao A; Jajodia A
    Indian J Radiol Imaging; 2021 Apr; 31(2):345-349. PubMed ID: 34556917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.